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Evaluation of mutation screening as a first line test for the di-
agnosis of the primary hyperoxalurias.
Background. A definitive diagnosis of primary hyperoxaluria
type 1 (PH1) and primary hyperoxaluria type 2 (PH2) re-
quires the measurement of alanine:glyoxylate aminotransferase
(AGT) and glyoxylate reductase (GR) activities, respectively, in
a liver biopsy. We have evaluated a molecular genetic approach
for the diagnosis of these autosomal-recessive diseases.
Methods. Polymerase chain reaction (PCR) was used to de-
tect three common mutations in the AGXT gene (c.33 34insC,
c.508G>A, and c.731T>C) and one, c.103delG, in the GRHPR
gene in DNA samples from 365 unrelated individuals referred
for diagnosis of PH1 and/or PH2 by liver enzyme analysis.
Results. One or more of these mutations was found in 183
(68.8%) biopsy proven cases of PH1 and PH2 with a test nega-
tive predictive value of 62% and 2%, respectively. 102 (34.1%)
patients were homozygous or compound heterozygous, making
a molecular diagnosis possible. Age of onset and presenting fea-
tures were similar in patients homozygous for any of the four
mutations. Of the AGXT homozygotes, only the c.508G>A mu-
tant was associated with significant AGT catalytic activity and
in two of these activity was in the low normal range, possibly
reflecting variation in mitochondrial content of the biopsy as
this particular mutation is associated with mitochondrial mis-
targeting.
Conclusion. Limited mutation analysis can provide a useful
first line test for PH1 and PH2 in patients in whom primary
hyperoxaluria is suspected and in whom secondary causes have
been excluded. Those patients in whom a single mutation, or
no mutation, is found can then be selectively targeted for liver
biopsy.
1The nomenclature used in this paper is based on that recommended by
Antonarakis SE, and the Nomenclature Working Group (1998): Rec-
ommendations for a nomenclature system for human gene mutations.
Hum Mutat 11:1–3, 1998, where “c” denotes cDNA sequence and nu-
cleotide numbering uses the “A” of the ATG translation initiation start
site as +1.
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The primary hyperoxalurias (PH) are a group of in-
herited disorders of endogenous oxalate overproduction
characterized by markedly elevated urinary oxalate, cal-
cium oxalate stone disease, and early onset of renal fail-
ure. The pathogenesis of two of these disorders, types 1
(PH1) (OMIM 604285) and 2 (PH2) (OMIM 604296),
is now recognized to be the result of mutations in the
AGXT and GRHPR genes encoding the enzymes ala-
nine:glyoxylate aminotransferase (AGT) (E.C. 2.6.1.44)
and glyoxylate reductase (GR) (E.C. 1.1.1.79), respec-
tively. AGT is liver specific [1] and catalyzes the per-
oxisomal metabolism of glyoxylate to glycine, while GR
plays a role in the reduction of cytosolic glyoxylate and
is predominantly, but not exclusively, hepatic in protein
distribution [2]. Definitive diagnosis of both diseases cur-
rently requires a needle liver biopsy and measurement
of AGT and GRHPR activities. This analysis is restricted
to a small number of centers worldwide and requires the
sample to be shipped frozen. It has been suggested that
a molecular approach may be beneficial for the diagno-
sis of PH1 [3]. This approach may involve sequencing
the whole coding region, although this is not necessarily
foolproof as mutations may lie in noncoding regions or
be synonymous changes which affect splicing. Alterna-
tively, one could use limited mutation analysis as a first
line test which may remove the necessity for biopsying
all patients.
The AGXT gene encoding the AGT protein is located
at the telomeric end of the long arm of chromosome 2,
2q37.3 and is composed of 11 exons covering approxi-
mately 10 kb of genomic DNA [4]. The gene is notable
for having a number of polymorphisms which affect the
amino acid composition [5, 6] and in particular for one
polymorphism, Pro11Leu, which introduces a weak mi-
tochondrial targeting sequence at the N-terminal [7]. The
functional consequence of this change is particularly noti-
cable in the presence of an additional missense mutation,
Gly170Arg (c.508G>A) that slows dimerization of the
protein. The Leu11, Arg170 variant is mistargeted to the
mitochondrion where it is unable to play its role in glyoxy-
late detoxification [8]. More than 45 mutations have been
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described in this gene to date (recently reviewed in [9]),
including missense, nonsense, splicing, minor insertions
and deletions, and major deletions. Some of these changes
occur only on the Leu11 polymorphic variant (the so-
called minor allele) and it is possible that the changes
are nonpathologic if occurring in tandem with the Pro11
polymorphism. For example, the Ile244Thr (c.731T>C)
mutation has approximately 50% of normal activity when
expressed with Pro11 but less than 5% of activity when
expressed in conjunction with Leu11 [5]. Some mutations
are relatively common, the Gly170Arg (c.508G>A) mu-
tation accounting for approximately 25% mutant alleles
[10] and Ile244Thr (c.731T>C) mutation approximately
9% [11].
Fourteen mutations have been described in the
GRHPR gene of which one, c.103delG is relatively com-
mon, although this mutation does appear to be restricted
to those of Caucasian origin [2, 12].
In this paper we have evaluated a strategy of screen-
ing for three common mutations, c.33 34insC, c.508G>A,
and c.731T>C in the AGXT gene, and the c.103delG
mutation in the GRHPR gene for the molecular diag-
nosis of PH1 and PH2, respectively. In addition, we have
reviewed the residual enzyme activity and clinical pre-
sentation of patients homozygous for these mutations to
establish whether any clinical or biochemical phenotype
is present.
METHODS
Liver and blood samples from 365 patients with
suspected primary hyperoxaluria were referred to the
University College London Hospitals (UCLH) Primary
Hyperoxaluria service, London, UK (N = 329) or to the
Biochemical Genetics laboratory, Vancouver, Canada (N
= 36). Liver AGT catalytic activity was determined as
previously described [13, 14]. Results were expressed as
% mean normal activity to allow comparisons between
laboratories. Immunoreactive AGT was determined by
Western blotting as previously described [13, 15]. Clini-
cal data regarding age of onset of disease, presentation,
and date of end-stage renal failure were obtained from
details received at time of biopsy. A further four pa-
tients with a diagnosis of PH2 made by hyperoxaluria
and L-glycericaciduria and found to be homozygous for
the c.103delG mutation were included in the phenotype
analysis for PH2.
The c.33 34insC, c.508A, and c.731C mutations in
AGXT and c.103delG mutation in GRHPR were ana-
lyzed by amplification of genomic DNA and restriction
enzyme digestion using primers and conditions previ-
ously documented [2, 8, 11] [Coulter-Mackie, manuscript
submitted].
Mutation nomenclature is based on cDNA se-
quence (GenBank sequences NM 000030 for AGXT and
NM 012203 for GRHPR).
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Fig. 1. Alanine:glyoxylate aminotransferse (AGT) catalytic and im-
munoreactivity in patients homozygous for the three common muta-
tions c.33 34insC, c.508A, and c.731C. Activity is expressed as % mean
normal to permit comparison between laboratories.
RESULTS
Evaluation of screening method for diagnosis of PH1
and PH2
Of 287 patients with biopsy-proven PH1, 179 tested
positive for at least one of the three common mutations
in AGXT, thus the test sensitivity (test positives/all with
PH1) was 62.3%. Of these, 99 (34.5%) were homozygous
or compound heterozygous for c.508A, c.33 34insC and
c.731C, confirming a diagnosis of PH1. The test had a
negative predictive value (true negative/true negatives +
false negatives) of 42%. The frequency of the c.33 34insC,
c.508A, and c.731C mutations in these 287 PH1 patients
was 12%, 27%, and 6%, respectively; the three mutations
therefore account for approximately 45% mutant alleles
in this gene.
Of the 12 PH2 patients in whom a liver biopsy result
was obtained, four tested positive for the c.103delG mu-
tation giving a test sensitivity of 33%; a diagnosis of PH2
could be made by molecular means in three cases ho-
mozygous for the change. However, the predictive value
of a negative result was only 97.8% largely as a result of
the smaller number of biopsies from PH2 patients.
Biochemical phenotype of homozygotes for the common
mutations found in the AGXT
The enzyme activity and immunoreactivity found in
liver biopsies of individuals homozygous for the three
mutations is shown in Figure 1; only c.508A was as-
sociated with significant in vitro enzyme activity. As
expected for a mutation which leads to a frameshift and
premature termination, biopsies from individuals with
the 33 34insC insertion mutation all had activity at or
below the method sensitivity and the majority were neg-
ative for immunoreactive protein. AGT containing the
missense mutation c.731C had very little catalytic activity
Rumsby et al: Mutation screening in PH1 and PH2 961
0
2
4
6
8
10
12
14
16
N
um
be
r o
f p
at
ie
nt
s
<1 1-10 11-2021-3031-40 >40
Age, years
33_34insC
508A
731C
103delG
Fig. 2. Age of presentation for the c.33 34insC, c.508A, c.731C muta-
tions in AGXT and for c.103delG in GRHPR. Information was available
on 84 homozygotes.
and was only weakly positive (less than 25% of control)
for immunoreactivity suggesting that an unstable protein
is produced. The widest spread of activity was seen with
the c.508A mutation. In two cases, one initially present-
ing with urolithiasis and both subsequently developing
end-stage renal failure, activity was at the low end of the
normal range and the final diagnosis of PH1 relied on
molecular analysis. These two subjects were counted as
false negatives for the enzyme test giving enzymology a
sensitivity of approximately 99%.
Biochemical phenotype of homozygotes for the 103delG
mutation in GRHPR
Only three liver biopsies were obtained from patients
homozygous for this mutation. GR activities were 0, 3,
and 13 nmol/min/mg (reference range 49 to 213). All had
AGT enzyme activity within the reference range.
Age and mode of presentation
There was no apparent difference in the age of pre-
sentation of individuals homozygous for any of the four
mutations analyzed, the majority of cases presenting be-
low the age of 10 years (Fig. 2).
For the three AGXT mutations there was no dif-
ference in the mode of presentation; renal stones and
renal failure being the primary presenting features
(Table 1). In the c.103delG homozygotes renal stones
were the predominant feature although the number of
patients is small.
DISCUSSION
Molecular genetics has the potential to provide a non-
invasive diagnosis of primary hyperoxaluria. A pragmatic
approach which is both affordable and relatively quick
would be to offer limited mutation analysis. This ap-
proach, when tested on a large group of patients with
PH1 and PH2, identified three groups: (1) those in whom
two mutations were found and therefore a firm diagno-
sis was possible (34.1%); (2) a group in whom a single
mutation was identified, increasing the clinical support
for a diagnosis of PH, but needing confirmation by liver
biopsy; (3) the group who were negative for all common
mutations and in whom a diagnosis of PH could not be
excluded and thus would require a liver biopsy.
With the advent of modern sequencing equipment, it
is feasible to sequence the whole gene but even with this
approach mutations are not always found [3]. In addi-
tion, the significance of previously unrecognized muta-
tions cannot be assumed. AGT itself has a number of
polymorphisms, which change the amino acid sequence
[8] but have no apparent pathologic effect [7]. Equally,
there are others which do and which appear to act in con-
cert with mutations increasing the severity of disease [5].
Finally, the cost of whole gene sequence analysis is not
insignificant and would require more staff time and re-
sources to be found. For this reason we decided to eval-
uate an approach based on what are quantitatively the
most frequent mutations causing PH1 and PH2. Two of
the mutations in the AGXT gene, c.33 34insC and c.508A,
occur in all ethnic groups and are associated with the ma-
jor and minor alleles respectively. In the present study,
these two mutations have allele frequencies of 12% and
27%, respectively, the latter agreeing with earlier figures
from this department on a smaller group of patients [10].
The high frequency of c.33 34insC has not been previ-
ously described although this mutation has been reported
in a variety of ethnic groups [3, 16]. The c.731C muta-
tion, like c.508A, is associated with the minor allele but
is commonly found in individuals of Spanish and North
African origin [17]. The frequency found in the present
study is slightly lower than that previously described by us
[11], possibly reflecting the lower number of individuals
of North African/Spanish origins in the larger cohort. The
c.103delG mutation in PH2 accounts for approximately
37% of cases of the disease [2] but appears to be restricted
to those of Caucasian origin [2, 12]. Therefore, depend-
ing on the ethnicity of the referring population, it may
be necessary to vary the selection of mutations tested
for, although unless these occur at a frequency greater
than 5% to 10%, little benefit will be gained from ex-
panding the mutation base. For example, in the samples
referred to the Canadian laboratory, c.731C represented
only 2.8%, whereas c.454A (Phe152Ile) was more com-
mon at 6.8%. An alternative strategy currently being ex-
plored [Williams, unpublished observations] would be to
include screening of individual exons showing a high den-
sity of mutations or to extend testing in any symptomatic
patient found to be heterozygous for one of the common
changes to include a limited number of less common but
recurrent mutations.
While a reasonable sensitivity was achieved by muta-
tion analysis for PH1 as a first screen in a patient pre-
senting with hyperoxaluria or symptoms suggestive of
endogenous oxalate overproduction, the sensitivity for
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Table 1. Comparison of modes of presentation of patients homozygous for three common mutations in the AGXT gene and c.103delG in GRHPR
AGXT mutations GRHPR
mutation
Presenting features c.33 34insC c.508A c.731C 103delG
Stones 13 (56%) 18 (53%) 8 (57%) 4 (66%)
Nephrocalcinosis 5 (22%) 5 (15%) 0 2 (34%)
Renal failure 5 (22%) 9 (28%) 4 (28%) 0
Other 2 (5%) (1 metabolic 2 (6%) 2 (14%) (UTI)
acidosis, 1 systemic (1 pyelonephritis,
oxalosis) 1 pancytopenia)
Total 24 34 14 6
UTI is urinary tract infection.
PH2 is poor. The sensitivity will fall still further if careful
assessment of individual patients is not done to exclude
secondary causes of hyperoxaluria. Additional biochem-
ical analyses, such as urinary glycolate, can be used to
support a presumptive diagnosis of PH1 but glycolate is
normal in approximately one third of cases and has been
shown to be raised in some cases which do not have the
disease [18]. Conversely, L-glycericaciduria is still of use
for the diagnosis of PH2, but it should be noted that the
converse is not true (i.e., lack of glycericaciduria cannot
exclude PH2 [19]).
The specificity of genetic testing would be expected to
equate to the carrier frequency providing the analytical
test is reliable. By chance, one might expect a PH1 car-
rier in 0.02% of the normal population [20]; the carrier
frequency of PH2 is as yet unknown but is likely to be sim-
ilar to, or less than, PH1. However, these figures are only
estimates as a patient presenting with stones in later life
is less likely to have a metabolic evaluation for their dis-
ease. Carriers would not be expected to be symptomatic
but there is a very small chance of detecting a mutation in
an individual who is a carrier but has hyperoxaluria from
some other cause. However, the protocol we propose is
that finding of a single mutation only, in a symptomatic
subject, should initiate analysis by liver biopsy for confir-
mation.
Genotype-phenotype correlations have been at-
tempted [21] but are difficult unless homozygosity is
present. Two of the three AGXT mutations screened
for in the present study, 33 34insC and c.731C, are es-
sentially null alleles with little residual enzyme activity
and as such, it is not surprising that the age of onset is
very similar for both with the majority below the age of
10 years, consistent with single reports in the literature
[3, 16]. Perhaps more interesting are those exceptions
who, with the same severe mutations, do not present un-
til the third or fourth decade. These exceptions emphasize
the difficulties of assigning any genotype-phenotype rela-
tionship and highlight the potential importance of other
genes or the environment in the course of the disease.
By contrast, the c.508A mutation produces a protein
but it folds slowly [22] and has a tendency to mistar-
get to the mitochondrion [8]. The enzyme still has cat-
alytic activity in vitro but is in the wrong place in vivo
and therefore ineffective in glyoxylate metabolism. One
might surmise that if any correctly folded protein was
taken into the peroxisome, it would function relatively
normally and thus one might expect a milder course of
disease. However, there was no difference in age of onset
of disease in this patient group compared with the other
mutations, therefore if one might regard end-stage renal
failure and/or death as a mark of severity, of 24 patients
who had reached this stage, nine had done so by age of
20 years. This contrasts sharply with the Italian findings
[16] where none of their five homozygotes for the c.508A
mutation had achieved end-stage renal failure before age
20 years.
The combination of molecular and biochemical anal-
ysis is a very powerful tool for the diagnosis of the pri-
mary hyperoxalurias. For example, two cases with AGT
enzyme activity in the low normal range, were misdiag-
nosed as “normal” in the absence of molecular results.
The apparent normal catalytic activity in biopsies from in-
dividuals homozygous for the c.508A mutation may arise
from variation in the number of mitochondria in a partic-
ular cell type; catalytic activity itself gives no indication
of how much enzyme is correctly located in the peroxi-
somes and therefore potentially functional in vivo, and
how much is in the mitochondria and nonfunctional.
CONCLUSION
A preliminary screen for limited mutations in the
AGXT and GRHPR genes can serve as a useful first line
investigation for PH with less risk than a liver biopsy.
However, molecular genetics can only offer a diagnosis in
approximately one third of cases, liver biopsy is required
for the remainder.
Reprint requests to Dr Gill Rumsby, UCL Hospitals Clinical Bio-
chemistry, 60 Whitfield St, London W1T 4EU, United Kingdom.
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